Dr. Helmut O. Steinberg, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 85
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TN license 49393 · IN license 01044306
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
Medical groups
- Ut Medical Group Inc (96 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 85
- Services billed
- 281
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 69 | 32 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 67 | 34 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 45 | 41 |
| Insertion of needle into vein for collection of blood sample | 31 | 18 |
| Blood glucose (sugar) test performed by hand-held instrument | 27 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Memphis, TN | 60 |
| Metformin Hcl Other prescribers in Memphis, TN | 57 |
| Ozempic (semaglutide) Other prescribers in Memphis, TN | 52 |
| Trulicity (dulaglutide) Other prescribers in Memphis, TN | 52 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Memphis, TN | 32 |
| Levothyroxine Sodium Other prescribers in Memphis, TN | 30 |
| Jardiance (empagliflozin) Other prescribers in Memphis, TN | 29 |
| Methimazole Other prescribers in Memphis, TN | 25 |
| Atorvastatin Calcium Other prescribers in Memphis, TN | 23 |
| Humulin 70-30 (insulin nph hum/reg insulin hm) Other prescribers in Memphis, TN | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 8 payments worth $368 in total to this clinician.
| Sequel Med Tech, LLC | $147 |
|---|---|
| Neurocrine Biosciences, Inc. | $103 |
| Insulet Corporation | $50.48 |
| Madrigal Pharmaceuticals | $26.83 |
| Corcept Therapeutics | $22.73 |
| Dexcom, Inc. | $18.62 |
| Food and Beverage | $368 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $55,351 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.